Table 3.
Efficacy outcomes by region (placebo plus chemotherapy arm)
| Region | Number of events | Median, months (95% CI) | Hazard ratioa (95% CI) |
|---|---|---|---|
| Overall survival | |||
| USA/western Europe (n = 81) | 72 | 9.1 (6.9–14.4) | – |
| Eastern Europe/South America (n = 118) | 105 | 7.3 (6.4–8.7) | 1.47 (1.09–1.99) |
| Korea and other Asia (n = 94) | 84 | 11.6 (9.1–15.6) | 0.91 (0.67–1.25) |
| Japan (n = 94) | 87 | 14.1 (10.9–17.6) | 0.87 (0.64–1.19) |
| Progression-free survival | |||
| USA/western Europe (n = 81) | 75 | 4.4 (4.0–5.7) | – |
| Eastern Europe/South America (n = 118) | 111 | 4.4 (4.0–5.4) | 1.19 (0.89–1.59) |
| Korea and other Asia (n = 94) | 93 | 5.6 (4.8–6.5) | 1.01 (0.74–1.37) |
| Japan (n = 94) | 92 | 5.7 (5.1–7.0) | 0.96 (0.71–1.31) |
CI confidence interval
aCompared with USA/western Europe